Monday, February 2, 2026
17.1
C
Bengaluru
Hot topics
Digital Therapeutics: New Frontiers in Healthcare
“If we look at major trends, people are living longer, on average, so there’s a rise in chronic diseases associated with aging. Meanwhile, healthcare workers are in short supply, and physicians and nurses do not have enough time for patients. Yet everyone has powerful computers in their pockets that give them access to technology, education, and information. Put all that together, and it’s the perfect moment for digital solutions to come to the market, change behavior, and enhance health outcomes at scale”
- Bozidar Jovicevic, Global head of Digital Therapeutics, Sanofi
Medical Rep to Chairman & Managing Director – Sunil Attavar’s Success Story
Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma?
My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well.
I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience.
I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.
Cipla–Pfizer Deal: How “Ordinary” Brands Are Fueling an Extraordinary Power Shift in Indian Pharma
What’s really happening in the Cipla–Pfizer tie‑up
At first glance,...
Biocon Bats for Affordable Insulin and Ozempic
🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Hot topics
Decoding Indian Pharma’s Approach to Digital Adoption and Transformation in a COVID-19 Constrained World
First Ever India Centric Survey: A CredoWeb - MedicinMan Research Project
Can Medicines Inject the Vitamins Amazon is Missing?
How Amazon’s Healthcare Bet May Change Indian Diagnostics and...
Doctors Still Considered Noble
The July 2016 issue of MedicinMan with articles by Piyush Agarwal, K. Hariram, Vivek Hattangadi, Anjali Sharma, Chandan Kumar, RB Balakrishna and Pankaj Mehrotra
Violence Against Doctors: Doctor-Patient Relationship Bruised and Battered
If a business fails, it was an idea that didn’t work. If treatment fails – it must be a botch up. A broken gadget may be beyond repair, but not a patient in a doctor’s hands. From such ungraded expectations stems the potential for things to take an ugly turn.
An unwanted profession dealing with an unwanted condition, namely Ill health:
If possible, we would wish away death and diseases, hospitals and doctors. A hospital is not a holiday resort, but it too costs money. And the scenario of an adverse outcome like death simply becomes unacceptable.
Interesting, Engaving & Relevant
In this issue Deepak Sharma talks about his journey from Medical Rep to Country Manager. Deeksha Fouzdar presents a case study on implementation of a competency-based HR system in Pharma. Other articles by K. Hariram and Vivek Hattangadi
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Arjun Arunachalam: The Man Who Deleted Helium
For more than fifty years, the MRI industry treated...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
IQVIA vs. PharmaTrac: Indian Pharma Market Data
Here is an analytical blog comparing the IQVIA MFR...
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Orphan Drugs and Indian Pharma: Moving from Volume to Value?
Zydus’ ZYCUBO May Be the Proof Point the Industry...
Newsletter
Get important news delivered directly to your inbox and stay connected!